Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis

Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis

Cystic fibrosis is a genetic disease typically characterized by progressive lung damage and premature mortality. Pulmonary exacerbations, or flare-ups of the lung disease, often require hospitalization for intensive treatment. Approximately 25% of patients with cystic fibrosis do not recover their b...

Full description

Bibliographic Details
Main Authors: Andre Schultz, Julie A. Marsh, Benjamin R. Saville, Richard Norman, Peter G. Middleton, Hugh W. Greville, Matthew I. Bellgard, Scott M. Berry, Tom Snelling
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Pharmacology
Subjects:
adaptive trial
platform trial
Bayesian
cystic fibrosis
exacerbations
master protocol
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00301/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00301/full

Similar Items